非酒精性脂肪性肝病无创评分系统的长期结局预测能力
该研究在1173例欧洲三级中心NAFLD患者中评估NFS、FIB-4、BARD、APRI和HFS对纤维化分层及长期结局的预测能力。横断面分析显示HFS识别显著和进展期纤维化最佳,NFS和FIB-4检测肝硬化最佳;纵向随访62-110个月,NFS和FIB-4预测肝脏相关事件最佳,NFS预测HCC最佳,FIB-4和HFS预测总死亡率最佳,所有评分对肝外事件预测能力有限。
要点
- HFS识别显著和进展期纤维化最佳,NFS和FIB-4检测肝硬化最佳
- NFS和FIB-4预测肝脏相关事件最佳,NFS预测HCC最佳
- FIB-4和HFS预测总死亡率最佳,所有评分对肝外事件预测有限
核心结论
- NFS、HFS和FIB-4在纤维化横断面识别和长期结局预测方面均优于APRI和BARD,是NAFLD临床管理的有用工具。
研究设计与样本
- 在1173例来自三级中心的欧洲NAFLD患者中评估NFS、FIB-4、BARD、APRI和HFS,纵向数据采用基于NSS的Cox比例风险模型,重复5折交叉验证,从607例所有NSS可用的患者中采样测试。
主要发现
- 横断面分析中HFS识别显著纤维化(F0-1 vs. F2-4)AUC=0.758,识别进展期纤维化(F0-2 vs. F3-4)AUC=0.805。
- NFS和FIB-4检测组织学肝硬化最佳,AUC范围0.85-0.88。
- 纵向随访62-110个月,NFS和FIB-4预测肝脏相关事件最佳(c-index>0.7),NFS预测HCC平均c-index=0.9,FIB-4和HFS预测总死亡率最佳(c-index>0.8)。
- 所有NSS对肝外事件预测能力有限(c-index<0.7)。
关键数值与推荐
- HFS识别显著纤维化AUC=0.758,识别进展期纤维化AUC=0.805。
- NFS和FIB-4检测肝硬化AUC范围0.85-0.88。
- NFS和FIB-4预测肝脏相关事件c-index>0.7,NFS预测HCC平均c-index=0.9,FIB-4和HFS预测总死亡率c-index>0.8。
- 所有NSS预测肝外事件c-index<0.7。
临床怎么用
- 临床可优先选用NFS、HFS和FIB-4对NAFLD患者进行纤维化风险分层和长期结局预测。
- NFS和FIB-4可用于预测肝脏相关事件,NFS可用于预测HCC,FIB-4和HFS可用于预测总死亡率。
- 上述评分对肝外事件预测能力有限,临床需注意其适用范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-invasive scoring systems (NSS) are used to identify patients with non-alcoholic fatty liver disease (NAFLD) who are at risk of advanced fibrosis, but their reliability in predicting long-term outcomes for hepatic/extrahepatic complications or death and their concordance in cross-sectional and longitudinal risk stratification remain uncertain. METHODS: The most common NSS (NFS, FIB-4, BARD, APRI) and the Hepamet fibrosis score (HFS) were assessed in 1,173 European patients with NAFLD from tertiary centres. Performance for fibrosis risk stratification and for the prediction of long-term hepatic/extrahepatic events, hepatocarcinoma (HCC) and overall mortality were evaluated in terms of AUC and Harrell's c-index. For longitudinal data, NSS-based Cox proportional hazard models were trained on the whole cohort with repeated 5-fold cross-validation, sampling for testing from the 607 patients with all NSS available. RESULTS: Cross-sectional analysis revealed HFS as the best performer for the identification of significant (F0-1 vs. F2-4, AUC = 0.758) and advanced (F0-2 vs. F3-4, AUC = 0.805) fibrosis, while NFS and FIB-4 showed the best performance for detecting histological cirrhosis (range AUCs 0.85-0.88). Considering longitudinal data (follow-up between 62 and 110 months), NFS and FIB-4 were the best at predicting liver-related events (c-indices>0.7), NFS for HCC (c-index = 0.9 on average), and FIB-4 and HFS for overall mortality (c-indices >0.8). All NSS showed limited performance (c-indices <0.7) for extrahepatic events. CONCLUSIONS: Overall, NFS, HFS and FIB-4 outperformed APRI and BARD for both cross-sectional identification of fibrosis and prediction of long-term outcomes, confirming that they are useful tools for the clinical management of patients with NAFLD at increased risk of fibrosis and liver-related complications or death. LAY SUMMARY: Non-invasive scoring systems are increasingly being used in patients with non-alcoholic fatty liver disease to identify those at risk of advanced fibrosis and hence clinical complications. Herein, we compared various non-invasive scoring systems and identified those that were best at identifying risk, as well as those that were best for the prediction of long-term outcomes, such as liver-related events, liver cancer and death.
引用
- Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol. 2021. PMID: 34090928. doi:10.1016/j.jhep.2021.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。